DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Phase 2

Withdrawn

Conditions: Round Cell Liposarcoma
Myxoid Liposarcoma
Unresectable Soft Tissue Sarcoma
Stage III Soft Tissue Sarcoma AJCC v7
Stage IV Soft Tissue Sarcoma AJCC v7
Metastatic Soft Tissue Sarcoma

Interventions: Procedure: Biopsy
Other: Laboratory Biomarker Analysis
Drug: Trabectedin

First Posted Date: 2018-01-11

Last Posted Date: 2019-09-10

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03397186

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Soft Tissue Sarcoma
Recurrent Soft Tissue Sarcoma

Interventions: Biological: Pembrolizumab
Radiation: Radiation Therapy

First Posted Date: 2017-11-09

Last Posted Date: 2024-07-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT03338959

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis

First Posted Date: 2017-11-09

Last Posted Date: 2023-09-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT03338972

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Phase 1

Suspended

Conditions: Juvenile Myelomonocytic Leukemia
Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Undifferentiated Leukemia
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Acute Biphenotypic Leukemia

Interventions: Biological: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-31

Last Posted Date: 2025-04-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT03326921

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Drug: Fludarabine Phosphate

First Posted Date: 2017-09-11

Last Posted Date: 2025-04-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT03277729

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

MMF for HIV Reservoir Reduction

Phase 2

Completed

Conditions: Human Immunodeficiency Virus I Infection

Interventions: Drug: Mycophenolate Mofetil 500Mg Tab

First Posted Date: 2017-08-25

Last Posted Date: 2020-12-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 5

Registration Number: NCT03262441

Locations: 🇺🇸
2 West Clinic at Harborview Medical Center, Seattle, Washington, United States

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Aggressive Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Plasma Cell Myeloma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2017-08-11

Last Posted Date: 2025-02-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT03246906

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Phase 4

Withdrawn

Conditions: HER2/Neu Negative
Invasive Breast Carcinoma
Postmenopausal
Stage 0 Breast Cancer
Stage IA Breast Cancer

Interventions: Drug: Anastrozole
Drug: Exemestane
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tamoxifen Citrate
Drug: Toremifene Citrate

First Posted Date: 2017-08-03

Last Posted Date: 2018-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03238703

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Phase 2

Terminated

Conditions: Hematopoietic Cell Transplantation Recipient
Secondary Myelofibrosis
T-Cell Non-Hodgkin Lymphoma
Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hematologic and Lymphocytic Disorder
Venous Thromboembolism
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Biological: Platelet Transfusion

First Posted Date: 2017-06-22

Last Posted Date: 2019-10-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03195010

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Mindset Intervention for Nicotine Dependence

Not Applicable

Completed

Conditions: Smoking Cessation
Smoking (Tobacco) Addiction
Psychology, Social

Interventions: Behavioral: SmartQuit
Behavioral: Growth Mindset

First Posted Date: 2017-06-02

Last Posted Date: 2018-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 398

Registration Number: NCT03174730

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy